CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year.
5 reports, 2 independent
Updated Aug 31
Gone quiet
Reached 5 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CStone is advancing drug candidate CS2009 through trials while reporting a 500% year-over-year sales increase and seeking FDA consensus.Sub-event
CStone seeks global Phase III consensus for Pralsetinib; sales surge 500% YoY.1 source
Keep exploring
The entities involved
Related events
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- A product was launched in the U.S. market following FDA involvement.
- Market growth for bioidentical hormones is projected to reach $5.74 billion by 2031, while the FDA monitors market trends and shortages.
- FDA-approved products are being moved to Schedule III following a rescheduling order finalized by the DOJ and DEA, involving Curaleaf.